制度・支援
指定難病 — No.217

エプスタイン病

検索語 Ebstein Anomaly ・ 最終更新 2026-07-22 21:28 ・ 最新に更新

Data Sheet
指定 No.217
Src PubMed · CT.gov · jRCT

これは医療アドバイスではありません。診断・治療の判断は必ず主治医にご相談ください。論文や治験は「今わかっている研究の状況」を示すもので、効果を保証するものではありません。

( 01 )EVIDENCE / PUBMED · 5件

世界の論文

直近の研究を、やさしい日本語で

各論文の見出しにある「確からしさ」は、その研究がどれくらい信頼できるかの目安です。「理論段階」はまだ仮説に近く、下にいくほど多くの患者で検証されていて、「メタ解析」がもっとも信頼できます。

症例報告
MK-01 · PMID 42472201

Breaking the lead barrier: subcutaneous implantable cardioverter-defibrillator implantation in Ebstein anomaly with left ventricular noncompaction

Journal
HeartRhythm case reports(2026 Jul)
Authors
6名
Type
Case Reports, Journal Article
PubMedで原文を見る
観察研究
MK-02 · PMID 42469799

Outcome analysis of bioprosthetic valve replacement in patients aged ≥ 50 years with Ebstein's anomaly

Abstract / 原文

OBJECTIVE: Cone reconstruction has become the preferred surgical technique for Ebstein's anomaly (EA). However, some patients aged ≥ 50 years are unsuitable for repair due to severe leaflet dysplasia, marked annular dilation, or impaired right ventricular function. This study evaluates the clinical outcomes of domestic bioprosthetic valve replacement in patients aged ≥ 50 years with EA. METHODS: A retrospective analysis was conducted on 15 consecutive patients aged ≥ 50 years with EA who underwent initial bioprosthetic tricuspid valve replacement at the Department of Cardiovascular Surgery, Affiliated Hospital of Southwest Medical University, from June 2019 to August 2024. Preoperative evaluations included electrocardiography, echocardiography, chest CT, and coronary angiography. Operative times, cardiopulmonary bypass time, aortic cross-clamp time, perioperative complications, and mortality were recorded. Follow-up assessed cardiac function, valve performance, and cardiac chamber dimensions. RESULTS: Among the 15 patients (11 females, 4 males; mean age 55.0 ± 4.2 years), cardiopulmonary bypass time was 127.9 ± 20.4 min and aortic cross-clamp time 69.5 ± 17.5 min. One patient died of cardiogenic shock on postoperative day 8. The remaining 14 were discharged alive. During follow-up (1-39 months), 13 patients (92.6%) of 14 survivors were followed; no late deaths or reoperations occurred. Symptomatic improvement was observed in 12 patients. No moderate or severe tricuspid regurgitation or bioprosthetic stenosis was detected. CONCLUSION: Bioprosthetic valve replacement appears feasible with acceptable early outcomes in patients aged ≥ 50 years with EA who are unsuitable for cone reconstruction, significantly improving symptoms in most patients. These preliminary findings require validation in larger studies with longer follow‑up.

Journal
Journal of cardiothoracic surgery(2026 Jul)
Authors
4名
Type
Journal Article
PubMedで原文を見る
観察研究
MK-03 · PMID 42455297

The Right Atrium and Atrialised Right Ventricle are Associated with Cardiac Output During Exercise in Patients with Ebstein Anomaly of the Tricuspid Valve

Abstract / 原文

The right atrium (RA) and atrialised RV (aRV) may be important in determining exercise capacity in Ebstein anomaly (EA). We performed exercise testing and resting/exercise cardiac magnetic resonance imaging (CMRI) to examine associations between RA and aRV and left heart volumes, cardiac index and exercise capacity (%VO2max). In 13 un-operated EA patients (median age 13.5 years), indexed end-diastolic volumes were calculated from resting CMRI; right atrium (RAi), atrialised RV (aRVi), functional RV (fRVEDVi), left atrium (LAi) and left ventricle (LVEDVi). Systolic (SCRsys) and diastolic (SCRdias) septal curvature were measured. Pulmonary artery and aortic flow were measured at rest and peak exercise, and cardiac index (CI) calculated. CIex was strongly positively associated with %VO2max (r = 0.74, p = 0.01). RAi and aRVi, but not fRVEDVi, were negatively associated with %VO2max, CIrest and CIex. fRVEF was positively associated with %VO2max, CIrest and CIex. LAi, LVEDVi and LVEF were associated with %VO2max, CIrest and CIex. SCRdias was strongly negatively associated with aRVi (r=-0.89, p < 0.01) and RAi (r=-0.73,p < 0.01) but not with fRVEDVi (r =-0.34,p = 0.28). In multivariable models LVEDVi had the most significant influence on %VO2max, CIrest and CIex. In EA, volumes of the true RA and aRV but not fRV are associated with exercise capacity and cardiac output at rest and on exercise. Maintaining LV diastolic volume is a key determinant of exercise capacity in EA.

Journal
Pediatric cardiology(2026 Jul)
Authors
7名
Type
Journal Article
PubMedで原文を見る
観察研究
MK-04 · PMID 42449741

CCTA of Pediatric Congenital Right Heart Obstructive Lesions: A Pictorial Review

Abstract / 原文

Pediatric congenital right heart obstructive lesions encompass a spectrum of diseases that obstruct blood flow from the right atrium to the pulmonary artery. Right ventricular inflow obstructions include tricuspid valve abnormalities, such as Ebstein anomaly, tricuspid valve dysplasia, and tricuspid atresia. Right ventricular outflow obstructions include pulmonary valve stenosis, pulmonary atresia, and tetralogy of Fallot. Cardiac computed tomography angiography (CCTA) is a valuable tool for the diagnosis, treatment planning, and follow-up of these lesions. In this pictorial review, we highlight the diagnostic utility of CCTA in congenital right heart obstructive lesions, emphasizing its role in preoperative planning.

Journal
Diagnostics (Basel, Switzerland)(2026 Jun)
Authors
2名
Type
Journal Article, Review
PubMedで原文を見る
観察研究
MK-05 · PMID 42403552

Primary Tricuspid Regurgitation in ACHD: Diagnosis and Treatment

Abstract / 原文

Primary tricuspid valve regurgitation includes congenital and acquired disorders, especially Ebstein anomaly and tricuspid valve dysplasia. Severe tricuspid regurgitation causes progressive right atrial and ventricular dilation, arrhythmias, exercise intolerance, impaired left ventricular filling, and eventual biventricular dysfunction. Some patients remain minimally symptomatic for decades despite progressive disease. Poor prognostic factors include severe cardiomegaly, ventricular dysfunction, cyanosis, and arrhythmias. Surgical indications include symptoms, declining exercise capacity, cyanosis, progressive right ventricular enlargement or dysfunction, recurrent arrhythmias, and, in selected asymptomatic patients, severe regurgitation with right ventricular dilation. The Cone repair procedure restores native valve competence, improves right and left ventricular interaction, promotes reverse remodeling, and has low operative risk in experienced centers. Current evidence supports individualized and earlier surgical repair, preferably during childhood and in specialized centers, to improve ventricular function, quality of life, and long-term survival.

Journal
Methodist DeBakey cardiovascular journal(2026)
Authors
1名
Type
Journal Article, Review
PubMedで原文を見る
( 02 )TRIALS / JAPAN · 0件

日本で参加できる治験

現在 募集中のもの

日本で現在募集中の治験は見つかりませんでした。下の公式レジストリで条件を変えると見つかる場合があります。
( 03 )REGISTRY / jRCT

治験をもっと探す

日本の公式レジストリで全件を確認

上の一覧は ClinicalTrials.gov の一部です。日本国内の治験の多くは、日本の公式レジストリ jRCT にのみ登録されています。下記から最新の全件をご確認ください。

※ jRCTは自動の大量データ取得を禁じているため、本サービスはjRCTを自動収集せず、患者ご自身が公式サイトで検索できるリンクでご案内しています(規約順守)。

お金・介護・制度エプスタイン病の療養に使えるかもしれない公的サポートを調べる医療費・生活費・介護の支援制度と相談先を、あなたの状況に合わせてご案内(回答は端末内で完結)
( 04 )SUPPORT

患者会・相談窓口

一人で抱え込まないでください

同じ病気の患者・家族とつながる、制度や生活の相談をする、といったときの窓口です。

全国の相談先

※ お住まいの都道府県の「難病相談支援センター」でも、医療費助成や療養生活の相談ができます(難病情報センターから探せます)。